Les médicaments GLP-1 comme Ozempic font beaucoup parler d’eux pour la perte de poids.
Mais en ligne, on trouve beaucoup d’informations… et pas toujours les bonnes.
Alors comment ces médicaments agissent-ils vraiment dans le corps et le cerveau ?
👉 Glisse pour découvrir 4 faits clés.
Cette publication est une collaboration avec @camhnews.
Sources
- Managing your obesity | Obesity Canada
- GLP-1 Agonists: What They Are, How They Work & Side Effects | Cleveland Clinic | 2023
- Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation | The American Journal of Medicine | June 2025
- GLP-1 Mechanisms in the Brain – Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders | National Library of Medicine | May 2025
- Physiology, Hypothalamus | StatPearls – NCBI Bookshelf | May 2023
- Mesolimbic Pathway – an overview | ScienceDirect Topics
- The Science of Obesity | Canadian Adult Obesity Clinical Practice Guidelines – Obesity Canada & The Canadian Association of Bariatric Physicians and Surgeons | 2020
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review | International Journal of Molecular Sciences | November 2025
- The semaglutide era considering medication-related weight gain | Quick Takes Podcast – CAMH | July 2025
- Weight regain after cessation of medication for weight management: systematic review and meta-analysis | The BMJ January 2026
- GLP-1 diabetes and weight-loss drug side effects: « Ozempic face » and more – Harvard Health | Harvard Health Publishing – Harvard Medical School | February 2024
Partagez notre post original de Bluesky !
Voir notre post Instagram original !
